Shah and colleagues enrolled 22 adult patients with B-cell NHL or CLL in a phase 1 dose escalation/expansion study investigating the safety and efficacy of bispecific anti-CD20, anti-CD19 (LV20.19) CAR-T cells [188]. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.